AI developer Lunit will present nine studies featuring the company's AI pathology technology at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, being held October 20 to 24, 2023.
The abstracts will cover a variety of areas and include the following:
- AI for prediction of multiple druggable mutations in non-small cell lung cancer from H&E-stained images
- Lunit Scope IO for distinguishing mismatch repair deficiency from mismatch repair proficiency colon cancers by analyzing features in whole-slide images
- AI investigating the efficacy and safety of avelumab plus gemcitabine in leiomyosarcoma patients who failed first-line chemotherapy
- Analyzing HER2 expression with Lunit SCOPE HER2 in breast cancer cases proves effective in predicting FISH (Fluorescence In Situ Hybridization) positivity and therapy response
- Lunit SCOPE HER2 for assessment of HER2 expression and tumor-infiltrating lymphocyte density in biliary tract cancer
- AI-powered spatial analysis of tumor-infiltrating lymphocyte in advanced biliary tract cancer patients, who are planning to be treated with anti-PD-1 therapy
- Lunit SCOPE IO for the predictive role of immune phenotypes and Inflamed Score in metastatic colorectal cancer patients
- Lunit's AI-powered tumor-infiltrating lymphocyte density analysis in recurrent and metastatic head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors
The company highlighted that these studies show the potential of the Lunit Scope suite for cancer diagnosis and treatment.
